Crossmark

Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer

Published Online: 2021-03-20

Published Print: 2021-05

Authors

Isaacs, James

Anders, Carey

McArthur, Heather

Force, Jeremy https://orcid.org/0000-0002-3326-2715
Funding

Funding for this research was provided by:

METAvivor
License Information

Text and Data Mining valid from 2021-03-20

Version of Record valid from 2021-03-20
More Information

Article History

Accepted: 18 February 2021

First Online: 20 March 2021

Declarations

:

: James Isaacs declares that he has no conflict of interest.Carey Anders has received research funding from Puma Biotechnology, Eli Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1 Therapeutics, Zion, Novartis, and Pfizer; has received compensation from Genentech, Eisai, Ipsen, Seattle Genetics, AstraZeneca, and Novartis for service as a consultant; and has received royalties from UpToDate and Jones & Bartlett Learning.Heather McArthur has received research funding from Bristol-Myers Squibb, MedImmune, AstraZeneca, BTG, and Merck, and has received compensation from Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Pfizer, Puma Biotechnology, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Peregrine, Calithera, Daiichi Sankyo, Seattle Genetics, AstraZeneca, and TapImmune for service as a consultant.Jeremy Force has received compensation from NanoString Technologies, Exact Sciences, Pfizer, and OncoSec Medical for service as a consultant.

Document is current